Literature DB >> 26248366

Antimicrobial Susceptibility and SOS-Dependent Increase in Mutation Frequency Are Impacted by Escherichia coli Topoisomerase I C-Terminal Point Mutation.

Jenny Yang1, Thirunavukkarasu Annamalai2, Bokun Cheng1, Srikanth Banda2, Rakhi Tyagi1, Yuk-Ching Tse-Dinh3.   

Abstract

Topoisomerase functions are required in all organisms for many vital cellular processes, including transcription elongation. The C terminus domains (CTD) of Escherichia coli topoisomerase I interact directly with RNA polymerase to remove transcription-driven negative supercoiling behind the RNA polymerase complex. This interaction prevents inhibition of transcription elongation from hypernegative supercoiling and R-loop accumulation. The physiological function of bacterial topoisomerase I in transcription is especially important for a rapid network response to an antibiotic challenge. In this study, Escherichia coli with a topA66 single nucleotide deletion mutation, which results in a frameshift in the TopA CTD, was shown to exhibit increased sensitivity to trimethoprim and quinolone antimicrobials. The topoisomerase I-RNA polymerase interaction and the SOS response to the antimicrobial agents were found to be significantly reduced by this topA66 mutation. Consequently, the mutation frequency measured by rifampin selection following SOS induction was diminished in the topA66 mutant. The increased antibiotic sensitivity for the topA66 mutant can be reversed by the expression of recombinant E. coli topoisomerase I but not by the expression of recombinant Mycobacterium tuberculosis topoisomerase I that has a nonhomologous CTD even though the recombinant M. tuberculosis topoisomerase I can restore most of the plasmid DNA linking number deficiency caused by the topA66 mutation. Direct interactions of E. coli topoisomerase I as part of transcription complexes are likely to be required for the rapid network response to an antibiotic challenge. Inhibitors of bacterial topoisomerase I functions and interactions may sensitize pathogens to antibiotic treatment and limit the mutagenic response.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26248366      PMCID: PMC4576087          DOI: 10.1128/AAC.00855-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  38 in total

1.  Suppression of chromosome segregation defects of Escherichia coli muk mutants by mutations in topoisomerase I.

Authors:  J A Sawitzke; S Austin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

2.  Increased sensitivity to oxidative challenges associated with topA deletion in Escherichia coli.

Authors:  Y C Tse-Dinh
Journal:  J Bacteriol       Date:  2000-02       Impact factor: 3.490

Review 3.  Antimicrobials as promoters of genetic variation.

Authors:  Jesús Blázquez; Alejandro Couce; Jerónimo Rodríguez-Beltrán; Alexandro Rodríguez-Rojas
Journal:  Curr Opin Microbiol       Date:  2012-08-11       Impact factor: 7.934

4.  C-terminal domains of Escherichia coli topoisomerase I belong to the zinc-ribbon superfamily.

Authors:  N V Grishin
Journal:  J Mol Biol       Date:  2000-06-23       Impact factor: 5.469

5.  Exposure to diverse antimicrobials induces the expression of qnrB1, qnrD and smaqnr genes by SOS-dependent regulation.

Authors:  A Briales; J M Rodriguez-Martinez; C Velasco; J Machuca; P Díaz de Alba; J Blazquez; A Pascual
Journal:  J Antimicrob Chemother       Date:  2012-08-22       Impact factor: 5.790

6.  Conditional silencing of topoisomerase I gene of Mycobacterium tuberculosis validates its essentiality for cell survival.

Authors:  Wareed Ahmed; Shruti Menon; Adwait Anand Godbole; Pullela V D N B Karthik; Valakunja Nagaraja
Journal:  FEMS Microbiol Lett       Date:  2014-04-03       Impact factor: 2.742

Review 7.  Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success.

Authors:  Liam S Redgrave; Sam B Sutton; Mark A Webber; Laura J V Piddock
Journal:  Trends Microbiol       Date:  2014-05-16       Impact factor: 17.079

8.  The role of the Zn(II) binding domain in the mechanism of E. coli DNA topoisomerase I.

Authors:  Adriana Ahumada; Yuk-Ching Tse-Dinh
Journal:  BMC Biochem       Date:  2002-05-29       Impact factor: 4.059

9.  Carboxyl terminal domain basic amino acids of mycobacterial topoisomerase I bind DNA to promote strand passage.

Authors:  Wareed Ahmed; Anuradha Gopal Bhat; Majety Naga Leelaram; Shruti Menon; Valakunja Nagaraja
Journal:  Nucleic Acids Res       Date:  2013-06-14       Impact factor: 16.971

Review 10.  Mechanism of quinolone action and resistance.

Authors:  Katie J Aldred; Robert J Kerns; Neil Osheroff
Journal:  Biochemistry       Date:  2014-03-07       Impact factor: 3.162

View more
  6 in total

1.  Investigating direct interaction between Escherichia coli topoisomerase I and RecA.

Authors:  Srikanth Banda; Purushottam Babu Tiwari; Yesim Darici; Yuk-Ching Tse-Dinh
Journal:  Gene       Date:  2016-03-19       Impact factor: 3.688

2.  Deacetylation of topoisomerase I is an important physiological function of E. coli CobB.

Authors:  Qingxuan Zhou; Yan Ning Zhou; Ding Jun Jin; Yuk-Ching Tse-Dinh
Journal:  Nucleic Acids Res       Date:  2017-05-19       Impact factor: 16.971

Review 3.  The SOS system: A complex and tightly regulated response to DNA damage.

Authors:  Katarzyna H Maslowska; Karolina Makiela-Dzbenska; Iwona J Fijalkowska
Journal:  Environ Mol Mutagen       Date:  2019-01-07       Impact factor: 3.216

4.  Regulatory Effect of DNA Topoisomerase I on T3SS Activity, Antibiotic Susceptibility and Quorum- Sensing-Independent Pyocyanin Synthesis in Pseudomonas aeruginosa.

Authors:  Rong Yan; Shikun Hu; Ning Ma; Peiqing Song; Qingqing Liang; Huiqun Zhang; Yanqi Li; Lixin Shen; Kangmin Duan; Lin Chen
Journal:  Int J Mol Sci       Date:  2019-03-05       Impact factor: 5.923

5.  Interaction between transcribing RNA polymerase and topoisomerase I prevents R-loop formation in E. coli.

Authors:  Dmitry Sutormin; Alina Galivondzhyan; Olga Musharova; Dmitrii Travin; Anastasiia Rusanova; Kseniya Obraztsova; Sergei Borukhov; Konstantin Severinov
Journal:  Nat Commun       Date:  2022-08-04       Impact factor: 17.694

6.  Using rapid point-of-care tests to inform antibiotic choice to mitigate drug resistance in gonorrhoea.

Authors:  Carolin Vegvari; Yonatan H Grad; Peter J White; Xavier Didelot; Lilith K Whittles; Nicole E Scangarella-Oman; Fanny S Mitrani-Gold; Etienne Dumont; Caroline R Perry; Kim Gilchrist; Mohammad Hossain; Tatum D Mortimer; Roy M Anderson; David Gardiner
Journal:  Euro Surveill       Date:  2020-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.